


*Image*

*1642*

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
February 12, 2004 Date	 Shelley P.M. Fussey

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Thorpe and Ran

Serial No.: 09/998,833

Filed: November 30, 2001

For: COMBINED CANCER TREATMENT  
METHODS USING ANTIBODIES TO  
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Bansal, G.

Atty. Dkt. No.: 4001.002299

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be required. Even if an Official Action had been issued in the last few days, no fees would be required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the document listed in the accompanying Form PTO-1449 was not cited in a communication from a foreign patent office in a counterpart foreign application. The listed document was published in hard copy and electronic form in about January and/or February 2004. The listed document has a face date of January 15, 2004, which is less than three months before the filing of the present statement, and could not have been submitted before publication.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002299.

Respectfully submitted,  
Williams, Morgan & Amerson, P.C.  
Customer No. 23720



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

10333 Richmond, Suite 1100  
Houston, Texas, 77042  
(713) 934-4079

Date: February 12, 2004

Form PTO-1449 (modified)

Atty. Docket No.  
4001.002299Serial No.  
09/998,833

List of Patents and Publications for Applicant's

Applicant  
Philip E. Thorpe and Sophia Ran

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
November 30, 2001Group:  
1642U.S. Patent Documents  
*See Page*Foreign Patent Documents  
*See Page*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C80	Thorpe, "Vascular Targeting Agents as Cancer Therapeutics," <i>Clin. Can. Res.</i> , 10:415-427, 2004.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

